Protagenic therapeutics announces resolution of nasdaq deficiency notice

New york, ny / accesswire / march 21, 2024 / protagenic therapeutics, inc. (nasdaq:ptix), a biopharmaceutical innovator, regained compliance with nasdaq listing rule 5550(a)(2) as the closing bid price of shares of ptix has remained above $1.00 per share for ten consecutive trading days. this resolves the issue of potential delisting from nasdaq by may 19, 2024 that the company had been facing.
PTIX Ratings Summary
PTIX Quant Ranking